IL-23 Inhibitor Study for Schizophrenia
Part of Mental health clinical trials.
This study tests whether a new medication that targets immune system inflammation (IL-23) can help people with schizophrenia feel better. Researchers believe this immune approach might reduce symptoms when combined with regular antipsychotic treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old
- You have a schizophrenia or schizoaffective disorder diagnosis
- You've been on the same antipsychotic medication for at least 30 days, with a stable dose for at least 15 days
- You have a history of elevated AGA IgG antibodies (a blood marker showing immune activation)
- You are not currently taking immunosuppressive drugs, daily high-dose aspirin, or daily NSAIDs like ibuprofen
- You do not have an active infection (including HIV, hepatitis C, or tuberculosis) or certain brain/medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This study looks at how immune system health relates to brain changes in people with schizophrenia. It uses brain imaging and electrical activity tests to understand these connections.
This trial tests a new medication called SEP-363856 for people with schizophrenia who are currently having a severe flare-up of symptoms. It aims to see if the drug is safe and effective compared to a placebo.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.